Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 2, 2012, Pages 22-25

  Hubáček, Jaroslav A ^a   Dlouhá, Dana ^a   Adámková, Vera ^a,b   Lánská, Věra ^a   Češka, Richard ^c   Vrablík, Michal ^c  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Efficacy; Gene gender interaction; Polymorphism; SLCO1B1; Statin

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER 2; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TRANSPORT; DYSLIPIDEMIA; FEMALE; GENE; GENE INTERACTION; GENOTYPE; HUMAN; LIVER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 84871048970     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Akao H, Polisecki E, Kajinami K, Trompet S, Robertson M, Ford I, et al (2012). KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis. 220: 456-462.
2. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al (2010). Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One. 5: e9763.
3. Daly AK (2010). Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 11: 241-246.
4. Generaux GT, Bonomo FM, Johnson M, Doan KM (2011). Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica. 41: 639-651.
5. Hubácek JA, Pitha J, Stávek P, Schmitz G, Poledne R (2000). Variable expression of hypercholesterolemia in Apolipoprotein E2*(Arg136 → Cys) heterozygotes. Physiol Res. 49: 307-314. (Pubitemid 30646827)
6. Hubácek JA, Adámková V, Skodová Z (2005). Rare variant of apolipoprotein E (Arg136 → Ser) in two normolipidemic individuals. Physiol Res. 54: 573-575.
7. Hubacek JA, Adamkova V, Prusikova M, Snejdrlova M, Hirschfeldova K, Lanska V, et al (2009). Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics. 10: 945-950.
8. Hubacek JA, Vrablik M (2011). Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact. 26: 13-20.
9. Hubacek JA, Adamkova V, Lanska V, Dlouha D, Rynekrova J, Zlatohlavek L, et al (2012). Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. J Appl Biomed. 10: 19-28.
10. Mangravite LM, Medina MW, Cui J, Pressman S, Smith JD, Rieder MJ, et al (2010). Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol. 30: 1485-1492.
11. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for DNA extraction from human nucleated cells. Nucleic Acid Res. 16: 1215.
12. Minnich A, Weisgraber KH, Newhouse Y, Dong LM, Fortin LJ, Tremblay M, et al (1995). Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3′ (Arg136 → His): association with mild dyslipidemia and double pre-beta very low density lipoproteins. J Lipid Res. 36: 57-66.
13. Niemi M, Pasanen MK, Neuvonen PJ (2006). SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 80: 356-366. (Pubitemid 44465886)
14. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 16: 873-879. (Pubitemid 44772805)
15. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 82: 726-733. (Pubitemid 350114817)
16. Pasanen MK, Neuvonen PJ, Niemi M (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 9: 19-33. (Pubitemid 351560529)
17. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al (2008). SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 359: 789-799.
18. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361: 1149-1158. (Pubitemid 36398384)
19. Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, et al (2012). SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med. 50: 441-448.
20. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al (2009). Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2: 173-181.
21. Thunsdall-Pedoe H, Kuulasmaa K, Tolonen H, Davidson M, Mendis S. MONICA monograph and multimedia sourcebook. Thunsdall-Pedoe H, editor. Geneva: World Health Organisation, 2003.
22. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, et al (2007). SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol. 64: 346-352. (Pubitemid 47283861)